VIT 100
Alternative Names: ChelASE; ProliferASELatest Information Update: 22 Jul 2010
At a glance
- Originator Immusol
- Developer iTherX Pharmaceuticals
- Class Antipsoriatics; Eye disorder therapies; Skin disorder therapies
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glaucoma; Hypertrophic scars; Keloids; Proliferative vitreoretinopathy; Psoriasis
Most Recent Events
- 24 Aug 2007 This programme is still in active development
- 15 Apr 2003 Phase-I clinical trials in Hypertrophic scars in USA (Topical)
- 15 Apr 2003 Phase-I clinical trials in Keloids in USA (Topical)